Mérieux Développement Announces Equity Financing into Xeris Pharmaceuticals

Friday, May 19, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LYON, France and BOSTON, May 19, 2017 /PRNewswire/ --

Mérieux Développement has

recently concluded an equity investment into Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs. With this additional financing, Xeris Pharmaceuticals
expects to fund registration trials and the commercial launch of Xeris' lead product, G-Pen(TM) a novel glucagon injection for treatment of severe hypoglycemia, as well as clinical validation of novel products leveraging Xeris' unique formulation platform.

"I very much appreciate the insights and connections which Mérieux Développement has brought to us over the last few months," said Paul Edick, President and CEO of Xeris Pharmaceuticals, Inc. He continued: "We look forward to receiving additional contribution from our premier investors, to help further advance Xeris' portfolio and commercial strategy in the US and internationally."

François Valencony, General Manager of Mérieux Développement, added : "Xeris' team has unique capabilities and know-how allowing them to  develop products which we think can deliver substantial value to diabetes patients and healthcare systems globally, including the first soluble, stable, ready-to-inject glucagon for use by people with diabetes and other indications with currently high unmet medical needs."

About Xeris Pharmaceuticals, Inc. - http://www.xerispharma.com

Xeris is an Austin, Texas-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The company's proprietary XeriSol(TM) and XeriJect(TM) formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps. Xeris' proprietary formulation platforms have the potential to offer distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, long term room-temperature stability, elimination of reconstitution and refrigeration, all of which can lead to products that are easier to use by patients, caregivers, health practitioners, and can reduce costs for payers and the healthcare system.

About Mérieux Développement - http://www.merieux-developpement.com 

Mérieux Développement is the investment fund of Institut Mérieux specialized in venture capital and growth equity transactions in the healthcare and nutrition sectors. Mérieux Développement supports entrepreneurs and companies with products or services presenting worldwide innovation to Health. Mérieux Développement brings its expertise and international network to enable entrepreneurs to disrupt and create new markets. Mérieux Développement is an affiliate of Institut Mérieux, which employs around 16,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2016.

Contact communication - MxD North America L.L.C.  

Alix SIPAHI - communication@merieux-developpement.com - tel: +1-617-679-8000

SOURCE Merieux Developpement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store